Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verastem

6.21
+0.47008.19%
Post-market: 6.250.0400+0.64%19:54 EDT
Volume:1.02M
Turnover:6.18M
Market Cap:319.75M
PE:-1.70
High:6.28
Open:5.70
Low:5.70
Close:5.74
Loading ...

Verastem Names Matthew E. Ros as COO

MT Newswires Live
·
15 Jan

BRIEF-Verastem Oncology Names Matthew E. Ros As Chief Operating Officer

Reuters
·
15 Jan

Verastem appoints Matthew Ros as COO

TIPRANKS
·
15 Jan

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

THOMSON REUTERS
·
15 Jan

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Business Wire
·
15 Jan

Verastem Exercises Option Early to License Cancer Drug VS-7375 From GenFleet

MT Newswires Live
·
14 Jan

Verastem exercises early option to license VS-7375 from GenFleet Therapeutics

TIPRANKS
·
14 Jan

BRIEF-Verastem Oncology Exercises Option Early to License VS-7375

Reuters
·
14 Jan

Verastem Oncology Exercises Option Early to License VS-7375, an Oral Kras G12d (on/off) Inhibitor, From Genfleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

THOMSON REUTERS
·
14 Jan

Verastem Inc - to File U.S. Ind Application for VS-7375 in Q1 2025

THOMSON REUTERS
·
14 Jan

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Business Wire
·
14 Jan

BRIEF-Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA

Reuters
·
13 Jan

Verastem Oncology Announces Debt Refinancing With Oberland Capital and Strategic Commercialization Partnership With IQVIA to Support Potential Launch in Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

THOMSON REUTERS
·
13 Jan

Verastem Inc - Secures $150 Million Credit Facility and $7.5 Million Equity Investment

THOMSON REUTERS
·
13 Jan

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Business Wire
·
13 Jan

BRIEF-Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
08 Jan

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
08 Jan

Verastem price target raised to $16 from $13 at RBC Capital

TIPRANKS
·
07 Jan

RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk

MT Newswires Live
·
07 Jan

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Zacks
·
02 Jan